A. Sinclair Dunlop - 23 Jun 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for A. Sinclair Dunlop
Issuer symbol
APLS
Transactions as of
23 Jun 2022
Net transactions value
-$675,000
Form type
4
Filing time
24 Jun 2022, 17:15:49 UTC
Previous filing
25 Apr 2022
Next filing
29 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $675,000 -15,000 -5% $45.00 285,679 23 Jun 2022 Indirect Owner (Epidarex) F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.